Pharma label expert Schreiner MediPharm and SCHOTT Pharma, the specialist in drug containment and delivery solutions for medications, have been engaged in a partnership for several years. Its objective is to develop new smart concepts that add functional value to prefilled syringes.
At the PDA Universe of Pre-Filled Syringes and Injection Devices Conference in California, both companies have now for the first time presented a coordinated, newly developed solution to equip prefilled syringes with RFID. The combination of syringe and smart label opens up diverse opportunities to optimize hospital routines, among other things.
The partnership between Schreiner MediPharm and SCHOTT Pharma has previously been focused primarily on equipping COC syringes with analog functional labels. Now the two pharmaceutical packaging experts are digitizing prefilled syringes. What makes the new RFID-Labels special is the combination of marking the syringe with its unique, digital identity. This enables optimized processes in hospital inventory management and patient care and documentation as well as the identification of a medication and a medical device. In addition, digital first-opening indication to protect the integrity of the syringe is possible.
To successfully implement this innovation and to ensure impeccable RFID functionality in terms of good performance and adequate range, various characteristics of the prefilled syringe must be considered. Aside from the material such as COC, PP, or glass, which can affect range and trouble-free reading of the tag, syringe size and diameter play a decisive role: The smaller the syringe the less space for product marking and integration of the RFID chip. Plus, the smaller the tag the shorter usually its read range. In addition, the curvature may affect performance, especially in the case of small syringe diameters.
The dielectric properties of the medications contained in the syringe play a role as well. Especially water-based active ingredients have a negative impact on the radio transmission performance of a tag. This requires precise positioning of the RFID-Label and integrated inlay according to the liquid and fill level. Additionally, special data standards for identification and tracking on unit level such as UnitVisID or GS1 must be considered, which enable all relevant stakeholders to interpret and use the data, as well as integration in the respective infrastructure.
Schreiner MediPharm and SCHOTT Pharma adapt the solution to the customer’s specific requirements to ensure optimal functionality from production to final use. This helps enhance product safety and avoid potential medication errors.
The new solution from Schreiner MediPharm and SCHOTT Pharma was presented for the first time at the “PDA Universe of Pre-filled Syringes and Injection Devices Conference” from October 18 to 19, 2022 in the United States. Arne Rehm, Senior Product Manager RFID/NFC Solutions at Schreiner MediPharm, and Tom van Ginneken, Head of Global Product Management for SCHOTT TOPPAC®, delivered a joint presentation under the motto “Making Pre-filled Syringes Smart” at the event.
About Schreiner MediPharm
Schreiner MediPharm, a business unit of Schreiner Group GmbH & Co. KG based in Oberschleissheim near Munich, is a leading developer and manufacturer of innovative, multifunctional specialty labels and marking solutions with value-added benefits for the healthcare industry. Thanks to its strong solutions expertise and specialized know-how Schreiner MediPharm is a highly capable development partner and reliable quality supplier to leading pharmaceutical and medical device technology companies worldwide.
About SCHOTT Pharma
SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world – because human health matters. The portfolio comprises drug containment and delivery solutions for injectable drugs ranging from prefillable glass and polymer syringes, to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 65 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 900 patents and technologies developed in-house, a state-of-the-art R&D center in Switzerland, and around 130 employees in R&D, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA, headquartered in Mainz, Germany, is part of SCHOTT AG that is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,700 customers including the top 30 leading pharma manufacturers for injectable drugs and generated sales of EUR 650 million in the fiscal year 2021.
Traceability: Your catalyst for supply chain excellence
A strategic roadmap for building brand protection programs
The online sale of counterfeit automotive parts: An analysis of how online marketplace practices allow counterfeiters to put unsafe products in American consumers’ cars, and proposed solutions for minimizing the proliferation of counterfeits
(Automotive Anti-Counterfeiting Council)
The International Market for Brand Protection Solutions (with Special Focus on CHINA): A Techno-Economic Study including Market Sizing, Technologies, Solutions & Opportunities 2021-2026
October 2021 / Electronic (PDF)
Track And Trace Solutions Market Size, Share & Trends Analysis Report by Product, by Technology, by Application, by End-use, by Region, and Segment Forecasts, 2021 - 2028
May 2021 / 150 pages / Electronic (PDF)
Anti-Counterfeit Packaging Market by Technology, Application, and Geography - Forecast and Analysis 2021-2025
April 2021 / 120 pages / Electronic (PDF)
Anti-Counterfeit Packaging Market by Technology, End-Use Industry and Region - Global Forecast to 2025
August 2020 / 200 pages / Electronic (PDF)